- Homogeneous fluorescence polarization assay to screen for SAM-binding site inhibitors
- Designed for high-throughput screening
- Plate-based fluorescence polarization measurement (ex 575 nm, em 620 nm)
Most histone lysine methyltransferases contain a conserved domain (SET) that utilizes S-adenosyl-L-methionine (SAM or AdoMet) as a co-factor to catalyze the methylation of the epsilon amino group of lysine. Mixed-lineage leukemia (MLL1) is a member of the trithorax group (trxG)/Set1-like family of gene activators that contains histone methyltransferase activity specific for lysine 4 of histone H3. This methylation plays an important role in gene activation at various developmentally regulated loci, such as the Hox gene loci.
This fluorescence polarization assay is based upon a proprietary small molecule fluorescent probe* that binds to the SAM binding pocket in MLL1. Binding of the small molecule probe to MLL1 induces an increase in fluorescence polarization. Binding of the probe can be competed with the endogenous cofactor SAM or by the inhibitor sinefungin, but is unaffected by the histone H3 peptide substrate. The MLL1 SAM-Screener™ Assay is robust (Z’ >0.6) and exhibits a greater than 100 mP shift over a range of 0-500 nM MLL1. The assay is suitable for high-throughput screening in the provided 384-well plate or can be scaled to higher density plate formats (e.g., 1,536-well) if desired. *United States Patent 9,120,820